UK Markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.27-0.62 (-5.69%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close10.89
Bid10.19 x 900
Ask12.43 x 900
Day's range10.12 - 10.98
52-week range9.35 - 21.30
Avg. volume832,920
Market cap481.594M
Beta (5Y monthly)0.72
PE ratio (TTM)N/A
EPS (TTM)-3.83
Earnings date05 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.27
  • Business Wire

    Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences

    DURHAM, N.C., November 09, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.

  • Motley Fool

    Aerie Pharmaceuticals, inc (AERI) Q3 2021 Earnings Call Transcript

    Thank you for standing by, and welcome to the Aerie Pharmaceuticals Third Quarter 2021 Earnings Conference Call. It is now my pleasure to turn the floor over to Aerie's General Counsel, John LaRocca. With us today are Ben McGraw, Aerie's Interim Executive Chairman; Tom Mitro, Aerie's President and Chief Operating Officer; David Hollander, Aerie's Chief Research and Development Officer; Casey Kopczynski, Aerie's Chief Scientific Officer; and Jeff Calabrese, Aerie's Vice President of Finance and Principal Accounting Officer.

  • Zacks

    Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

    Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.